Adrenal tumors autonomously producing cortisol cause Cushing's syndrome 1-4 . We performed exome sequencing of 25 tumor-normal pairs and identified 2 subgroups. Eight tumors (including three carcinomas) had many somatic copy number variants (CNVs) with frequent deletion of CDC42 and CDKN2A, amplification of 5q31.2 and protein-altering mutations in TP53 and RB1. Seventeen tumors (all adenomas) had no somatic CNVs or TP53 or RB1 mutations. Six of these had known gain-of-function mutations in CTNNB1 (b-catenin) 5,6 or GNAS (Ga s ) 7,8 . Six others had somatic mutations in PRKACA (protein kinase A (PKA) catalytic subunit) resulting in a p.Leu206Arg substitution. Further sequencing identified this mutation in 13 of 63 tumors (35% of adenomas with overt Cushing's syndrome). PRKACA, GNAS and CTNNB1 mutations were mutually exclusive. Leu206 directly interacts with the regulatory subunit of PKA, PRKAR1A 9,10 . Leu206Arg PRKACA loses PRKAR1A binding, increasing the phosphorylation of downstream targets. PKA activity induces cortisol production and cell proliferation 11-15 , providing a mechanism for tumor development. These findings define distinct mechanisms underlying adrenal cortisol-producing tumors.
Adrenal tumors autonomously producing cortisol cause Cushing's syndrome [1] [2] [3] [4] . We performed exome sequencing of 25 tumor-normal pairs and identified 2 subgroups. Eight tumors (including three carcinomas) had many somatic copy number variants (CNVs) with frequent deletion of CDC42 and CDKN2A, amplification of 5q31.2 and protein-altering mutations in TP53 and RB1. Seventeen tumors (all adenomas) had no somatic CNVs or TP53 or RB1 mutations. Six of these had known gain-of-function mutations in CTNNB1 (b-catenin) 5, 6 or GNAS (Ga s ) 7, 8 . Six others had somatic mutations in PRKACA (protein kinase A (PKA) catalytic subunit) resulting in a p.Leu206Arg substitution. Further sequencing identified this mutation in 13 of 63 tumors (35% of adenomas with overt Cushing's syndrome). PRKACA, GNAS and CTNNB1 mutations were mutually exclusive. Leu206 directly interacts with the regulatory subunit of PKA, PRKAR1A 9,10 . Leu206Arg PRKACA loses PRKAR1A binding, increasing the phosphorylation of downstream targets. PKA activity induces cortisol production and cell proliferation [11] [12] [13] [14] [15] , providing a mechanism for tumor development. These findings define distinct mechanisms underlying adrenal cortisol-producing tumors.
Cortisol production is normally tightly regulated. Stress signals lead to hypothalamic release of corticotropin-releasing hormone (CRH) and vasopressin, inducing pituitary secretion of adrenocorticotropic hormone (ACTH), which binds its G protein-coupled receptor (melanocortin receptor 2) in adrenal fasciculata, activating adenylate cyclase [16] [17] [18] [19] . The resulting cyclic AMP (cAMP) binds the regulatory subunit of PKA, inducing release of the PKA catalytic subunit and thereby allowing phosphorylation of downstream targets such as CREB 20, 21 . This signaling induces cortisol biosynthesis and cell proliferation [21] [22] [23] .
Cushing's syndrome results from excessive cortisol production, causing metabolic abnormalities including central obesity, myopathy, diabetes, hypertension and osteoporosis 2, 24 . This syndrome arises from tumors that constitutively produce CRH or ACTH, or from adrenal tumors that autonomously produce cortisol 1 . Somatic activating mutations in CTNNB1 (encoding β-catenin) or GNAS (encoding Gα s , which activates adenylate cyclase) have been found in a subset of these adrenal tumors [5] [6] [7] [8] . Additionally, germline or mosaic mutations in GNAS, PRKAR1A (encoding the regulatory subunit of PKA) or cAMP phosphodiesterases (PDE11A or PDE8B) cause increased cAMP signaling and disorders that include Cushing's syndrome and adrenal hyperplasia [11] [12] [13] 15, [25] [26] [27] . Thus, increased cAMP signaling in adrenal fasciculata is sufficient to increase cortisol production and adrenal cell mass.
Nonetheless, the pathogenesis of the vast majority of adrenal tumors that autonomously produce cortisol is unknown. We initially studied 25 individuals diagnosed with tumors autonomously producing cortisol. Diagnosis was based on elevated 24-h urinary cortisol levels with suppressed ACTH levels and/or pathological dexamethasone suppression test (inability to suppress cortisol secretion with exogenous glucocorticoids, i.e., dexamethasone) along with the presence of an adrenal tumor 28 . Eleven subjects had clinical stigmata corresponding to Cushing's syndrome (Online Methods and Supplementary Table 1) . Surgical pathology identified tumors with a mean size of 5.2 cm in diameter; 22 tumors were classified as adrenocortical adenomas (ACAs) and 3 were classified as adrenocortical carcinomas (ACCs).
We performed exome sequencing on tumor and matched normal DNA. In total, 90% of the targeted bases in tumors had 20 or more independent reads (Supplementary Table 2 ). Mean tumor purity was estimated at 38%. We called somatic single-nucleotide variants (SNVs) and somatic CNVs (Online Methods), and we validated mutations of interest by direct Sanger sequencing.
Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors l e t t e r s
The results identified two distinct groups of tumors with qualitative differences in CNV number. Eight tumors (CNV positive; including all 3 carcinomas) had 13.4 ± 3.9 somatic CNVs (range of 7-18; Supplementary Fig. 1 ), whereas 17 (CNV negative) had no somatic CNVs. CNV-positive tumors had a higher somatic SNV mutation rate 0.8 versus 0.28 SNVs per megabase; P = 1.3 × 10 −3 , Mann-Whitney U test) and more protein-altering somatic mutations per tumor (16.1 versus 5.6; P = 8 × 10 −4 , Mann-Whitney U test; Fig. 1a) . These differences remained significant when carcinomas were removed from analysis (mutation rate of 0.54 SNVs per megabase, P = 0.02; 10.4 protein-altering mutations per tumor, P = 0.01).
CNV-positive tumors had significant focal losses of three chromosome segments (GISTIC 29 q value < 0.25; Fig. 1b and Supplementary Fig. 2) . Deletions of 1p36.12 and 9p21.3 included the cancer-related genes CDC42 and CDKN2A, respectively; the 10p12.33 deletion contained MIR511-1, which shows reduced expression in ACCs 30 . A focal gain at 5q31.2 (q value = 0.16) included WNT8A. Wnt signaling is a proliferative signal in the adrenal cortex 5 , and gain-of-function mutations affecting β-catenin are common in adrenal tumors 31 . Two CNV-positive tumors had known activating mutations in CTNNB1 (Supplementary Table 3) .
CNV-positive tumors also had somatic mutations in the cancerrelated genes TP53 and RB1, in all cases in segments with loss of heterozygosity (LOH; Fig. 1c) . Mutations in these genes were not found in CNV-negative tumors (P = 5.5 × 10 −3 , Fisher's exact test). LOH at TP53 in all cases resulted from loss of one entire copy of chromosome 17 ( Supplementary Fig. 1) ; TP53-associated cancers such as colon, lung and breast cancers typically have deletion confined to 17p [32] [33] [34] [35] . Interestingly, 17q includes PRKAR1A, raising the question of whether heterozygous deletion of PRKAR1A might contribute to cortisol excess in these tumors. No other genes were significantly mutated (Supplementary Table 3 ). Tumors clinically classified as adenomas in the CNV-positive group all had Weiss scores of 0 or 1 and, where studied, weak Ki-67 staining (Supplementary Table 1) , providing no histological evidence of carcinoma.
The remaining 17 tumors had a mean of only 1.6 silent and 5.6 protein-altering mutations (Fig. 1a) . Known gain-of-function somatic mutations 31, 36 were found in CTNNB1 (four tumors; encoding p.Ser45Pro or p.Asp32Gly substitution) or GNAS (two tumors; encoding p.Arg201His or p.Gln227Glu substitution) (Supplementary Table 3) .
Additionally, we found the identical somatic A>C mutation in PRKACA (encoding the α isoform of the catalytic subunit of cAMPdependent protein kinase A) resulting in a p.Leu206Arg substitution (c.617A>C, NM_002730.3) (Fig. 2a and Supplementary  Table 4 ), in six CNV-negative tumors. This mutation has not previously been reported (absent from >10,000 exomes in public and Yale databases and from the Catalogue of Somatic Mutations in Cancer, COSMIC). The read counts in all cases were consistent with heterozygous somatic mutations. These mutations were mutually exclusive with CTNNB1 and GNAS mutations (P = 0.043, Fisher's exact test; Fig. 1c ). We detected both wild-type and mutant PRKACA transcripts in tumor cDNA ( Supplementary  Fig. 3 ). No other genes were mutated in more than one tumor.
The segments of the PRKACA, GNAS and CTNNB1 genes harboring gain-of-function mutations were amplified by PCR of DNA from 31 additional cortisol-producing adrenal tumors and matched germline samples (available for 20 subjects) and underwent Sanger sequencing (Supplementary Table 1 ). Seven additional tumors without matched normal DNA had exome sequencing data available. In total, these samples comprised 33 ACAs and 5 ACCs. We identified the PRKACA mutation encoding p.Leu206Arg in 7 additional tumors, collectively in 13 of 63 tumors (21%; 24% of all ACAs and 35% of ACAs associated with overt Cushing's syndrome). The probability of finding an identical somatic mutation at any base in the exome 13 or more times by chance in 63 tumors is <1 × 10 −62 (binomial test). We also found activating CTNNB1 and GNAS mutations in a total of ten (15.9%) and three (4.8%) tumors, respectively. PRKACA, CTNNB1 and GNAS mutations remained mutually exclusive (P = 0.02, Monte Carlo simulation).
PRKACA encodes the most highly expressed catalytic PKA isoform in the human adrenal gland (Supplementary Table 5 ); the most highly expressed regulatory subunit is encoded by PRKAR1A. PRKACA phosphorylates the RRX(S/T)Φ motif (where X is any residue and Φ is a hydrophobic residue) 37 . The regulatory subunit binds to the PRKACA catalytic cleft via a pseudosubstrate sequence, RRGAI 9 ; the isoleucine of PRKAR1A fits into a hydrophobic cleft in the catalytic domain formed by Leu206 and Leu199 (Fig. 2c,d ) 10, 38, 39 . Leu206 is conserved in the proteins encoded by orthologs from invertebrates to humans, and yeast has the isomer isoleucine residue (Fig. 2b) . The p.Leu206Arg substitution is likely to disrupt this interaction (Fig. 2e,f) , resulting in constitutive PKA activity.
We expressed PRKAR1A and either wild-type or Leu206Arg PRKACA (both with a C-terminal Flag epitope tag) in equimolar amounts in HEK293T cells. Endogenous levels of PRKAR1A were low and were increased by transfection (Fig. 3a) . We performed immunoprecipitation in cell lysates with antibody to Flag to pull down PRKACA and then carried out protein blotting using antibody to l e t t e r s PRKAR1A. In three independent transfections, immunoprecipitation of wild-type PRKACA robustly pulled down PRKAR1A, whereas no PRKAR1A was detected after immunoprecipitation of Leu206Arg PRKACA (Fig. 3a) . Unbound Leu206Arg PRKACA should result in increased phosphorylation at target sites such as Ser133 of CREB. Protein blotting of lysates from cells expressing wild-type or mutant PRKACA and PRKAR1A with an antibody specific for CREB phosphorylated at Ser133 demonstrated that expression of Leu206Arg PRKACA resulted in ~4-fold higher levels of phosphorylated CREB than expression of wild-type PRKACA (P = 0.037, t test; Fig. 3b) . Similarly, increased phosphorylation was seen at Ser63 of ATF1, another PKA target (P = 0.002, t test; Fig. 3b) . Immunohistochemistry for CREB phosphorylated at Ser133 showed higher staining in eight PRKACAmutant tumors than in five adenomas without PRKACA, GNAS or CTNNB1 mutations (median percent of cells staining, 55% versus 10%; Supplementary Fig. 4 and Supplementary Table 6 Adenomas with PRKACA or GNAS mutations were significantly smaller than adenomas without these mutations (28.7 ± 7.3 mm versus 39.2 ± 15.9 mm in diameter, s.d.; P = 0.035, Mann-Whitney U test), and individuals with these tumors presented at significantly younger ages (45.3 ± 13.5 versus 52.5 ± 11.9 years, s.d.; P = 0.045, Mann-Whitney U test). These mutations were also significantly associated with overt Cushing's syndrome (13/16 with PRKACA or GNAS mutation with overt Cushing's syndrome versus 16/39 without these mutations; P = 0.008, Fisher's exact test).
These results implicate a recurrent gain-of-function mutation in PRKACA in cortisol-producing adrenal adenomas. PRKACA was the most frequently mutated gene in our cohort. Mutant PRKACA has drastically diminished binding to its regulatory subunit, leading to increased PKA enzymatic activity.
On the basis of strong previous evidence that increased cAMP signaling is sufficient for cell proliferation and cortisol production 7, [40] [41] [42] , these PRKACA mutations are likely sufficient for tumor formation (Supplementary Fig. 6 ). The absence of other mutations likely to . Cells expressing Leu206Arg PRKACA have three-to fourfold higher levels of phosphorylated CREB and ATF1 than cells expressing wild-type PRKACA (**P < 0.05). Neg, no transfection with constructs encoding PRKACA or PRKAR1A.
6 1 6 VOLUME 46 | NUMBER 6 | JUNE 2014 Nature GeNetics l e t t e r s contribute to neoplasia supports this notion. The same concept applies to activating GNAS mutations. These findings are analogous to observations in adrenal aldosterone-producing adenomas, in which single mutations are sufficient to induce cell proliferation and hormone production [43] [44] [45] . In both diseases, the coupling of signaling pathways to both hormone production and cell proliferation provides a mechanism for increasing the mass of hormone-producing cells when demand for hormone is high. These observations suggest that PKA inhibitors could be of benefit in controlling tumor growth and hormone production in tumors bearing the PRKACA mutation. We found mutations in PRKACA, GNAS and CTNNB1 in 12 of 17 CNV-negative tumors. The pathogenesis of the remaining five tumors without established driver mutations remains unknown, leaving open the question of whether these tumors might result from mutations outside the coding region.
The mutual exclusivity of PRKACA, GNAS and CTNNB1 mutations suggests that they phenocopy one another. Previous studies have found that increased cAMP signaling elevates Wnt/β-catenin signaling 46, 47 ; similarly, PKA can phosphorylate β-catenin, inhibiting ubiquitination and increasing signaling 48, 49 . Wnt signaling promotes the proliferation of adrenal fasciculata cells, and there is evidence that it has a role in activation of the steroid biosynthetic pathway 50 . Nonetheless, activating CTNNB1 mutations are also found in non-hormone-producing adrenocortical tumors and in other cancers 31, 51, 52 . Further work will be required to establish the factors that determine which tumors with CTNNB1 mutations autonomously produce hormones.
While this paper was under review, the same somatic PRKACA mutation was reported in 37% of adrenal adenomas associated with overt Cushing's syndrome and in 22% of all cortisol-producing adenomas from an independent cohort 53 . Use of a cell-based fluorescence resonance energy transfer (FRET) assay for PKA activity provided evidence of constitutive activity of the mutant protein 53 .
The striking differences in the mutation spectra of CNVpositive and CNV-negative tumors suggest two distinct mechanisms for these tumors. Interestingly, the somatic mutation spectrum of CNV-positive tumors diagnosed by rigorous histological criteria as adenomas was more similar to that of CNV-positive carcinomas and other cancers than to the one found in CNV-negative adenomas. Larger cortisol-producing adrenal tumors are believed to produce cortisol inefficiently owing to lack of activation of the cortisol biosynthetic pathway, whereas smaller tumors are more efficient owing to induction of cortisol biosynthetic enzymes 54 . The current findings support this observation, as smaller tumors more frequently have PRKACA and GNAS mutations activating the cAMP signaling pathway.
The mutation spectrum in CNV-positive adenomas suggests that they may have greater malignant potential. These tumors may come to early attention owing to clinical signs and symptoms of cortisol excess. Interestingly, some adrenal cortisol-producing tumors initially classified as benign have recurred with invasive or metastatic disease 55 . Similarly, other studies in mice and humans have also suggested a multistep model of progression from adrenal hyperplasia to adenoma and carcinoma [56] [57] [58] . These observations suggest that CNV-positive adenomas might warrant closer clinical follow-up.
Although all tumors in our study were diagnosed as having autonomous cortisol production by experienced endocrinologists and surgeons in tertiary referral hospitals, supporting data for nine subjects referred from outside hospitals had incomplete documentation in available medical records (Supplementary Table 1) . Exclusion of these tumors (14% of the total) did not substantially alter the conclusions. These nine tumors comprised three carcinomas and six adenomas with no mutation in PRKACA or GNAS and one with a CTNNB1 mutation.
Lastly, activating GNAS mutations are found in growth hormonesecreting pituitary tumors and thyroid adenomas 59 . The finding that PRKACA mutation can phenocopy activating GNAS mutations in adrenal tumors raises the possibility that mutations in PRKACA or other genes that increase cAMP signaling might be found in these other tumors as well.
METhodS
Methods and any associated references are available in the online version of the paper.
Accession codes. Somatic mutations found by exome sequencing have been deposited in ClinVar under the batch accession 24068. RNA sequencing data generated have been deposited in the Gene Expression Omnibus (GEO) under accession GSE56016. 
oNLINE METhodS
Subjects and specimens. Matched fresh-frozen cortisol-producing adrenocortical tumors and either venous blood samples or adjacent normal tissue were obtained from patients undergoing adrenalectomy at the Yale New Haven Hospital or Uppsala University Hospital. Additional tumors and matched normal samples were obtained from formalin-fixed, paraffin-embedded samples at the Yale Department of Pathology, the University of Bonn and the University of Düsseldorf. The study protocol was approved by local institutional review boards, and study participants provided written informed consent.
All tumors included in this study were determined by experienced endocrinologists and endocrine surgeons at tertiary referral hospitals to have ACTH-independent cortisol production, resulting in either subclinical or overt Cushing's syndrome at the time of surgery, with surgical pathology consistent with that diagnosis. Patient demographics, tumor characteristics, laboratory test results and clinical features are summarized in Supplementary  Table 1 . Some clinical records were incomplete owing to evaluation having been performed at outside hospitals, with detailed records missing from the tertiary hospital medical record.
Tumors were classified by an endocrine pathologist blinded to genotypes; tumor histology was categorized by gross assessment of the tumor, and the percentage of oncocytic cells and nuclear atypia was graded from unremarkable to severe atypia. Weiss scores 60, 61 were determined for each tumor, and the proliferative index was assessed by staining for Ki-67 (clone MIB-1, Dakopatts; 1:300 dilution; epitope retrieval: high pH for 20 min; Leica Bond III) in tumors on the judgment of the pathologist. The percentage of tumor cell nuclei staining for Ki-67 in 4,000 to 5,000 cells is reported.
DNA and RNA were isolated from samples that were not formalin fixed or paraffin embedded using the AllPrep kit (Qiagen) following the manufacturer's instructions. For formalin-fixed, paraffin-embedded samples, DNA was prepared with the BiOstic FFPE Tissue DNA Isolation kit (MO BIO Laboratories) using a modified protocol.
Whole-exome sequencing and analysis. Targeted capture was performed using the NimbleGen 2.1 Exome reagent followed by sequencing on the Illumina platform as previously described 44 . Sequences were aligned to NCBI Build 36 of the human genome using the ELAND program (Illumina). Somatic mutations were called on the basis of the significance of differences in reference and non-reference read distributions between tumor and matched normal samples. Calls were further evaluated by manual inspection of read alignments.
The somatic mutation rate and estimations of tumor purity were calculated as previously described 44 . MutSig 62 was used to determine whether genes were mutated more often than expected by chance. CNVs were identified by comparing the coverage depth ratios of tumor and matched normal samples after normalizing for the mean coverage depth of each exome and changes in minor allele frequency at informative SNPs. GISTIC2.0 was used to assess the significance of recurrent CNVs as described previously 29 .
Sanger sequencing of genomic DNA. Direct bidirectional Sanger sequencing of PRKACA codon 206 and exon 3 of CTNNB1 and GNAS (codons 201 and 227) from genomic DNA from tumors and matched normal samples was performed following PCR amplification using specific primers. Primer sequences are listed in Supplementary Table 7. Whole-transcriptome profiling. rRNA was removed from total RNA using the Ribo-Zero rRNA Removal kit (Epicenter) according to the manufacturer's instructions. cDNA was synthesized, and libraries were prepared using the Illumina RNA-Seq kit; sequencing was then performed on an Illumina HiSeq instrument. RNA sequencing data for normal adrenal gland were obtained from the Illumina Human Body Map 2.0 Project 63 . Sequences were aligned using TopHat version 2.08 and assembled into transcripts using Cufflinks (version 2.0.2) 64, 65 .
Clones and mutagenesis. Expression plasmids encoding human PRKACA and PRKAR1A were obtained from Origene (RC210332, NM_002730; RC203828, NM_002734). The mutation encoding p.Leu206Arg was introduced into PRKACA using the QuikChange site-directed mutagenesis system (Stratagene) and was validated by sequencing the complete coding region.
Plasmids were prepared using the HiSpeed Plasmid Maxi kit (Qiagen). The sequence encoding the Flag tag was deleted in the PRKAR1A construct for the immunoprecipitation experiments using EcoRV and PmeI restriction enzymes (New England BioLabs).
Transient transfection and immunoprecipitation. Mycoplasma-free HEK293T cells (ECACC) were cultured in DMEM (Gibco) supplemented with 10% FBS, penicillin (100 units/ml) and streptomycin (10 mg/ml). Cells were transfected with expression plasmids using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions and were incubated for 48 h. Constructs encoding PRKACA and PRKAR1A were cotransfected into cells at a molar ratio of 1:1. Cells were then washed in cold PBS and lysed at 4 °C in lysis buffer as previously described 66 . Protein concentrations were determined using a BCA Protein Assay kit (Pierce), and proteins were incubated with Anti-FLAG M2 Affinity Gel (Sigma) at 4 °C, washed and eluted with 3× Flag peptide.
Protein blotting. Protein extraction and blotting were performed as previously described 66 . Lysates and immunoprecipitates were fractionated on 4-20% polyacrylamide gels, transferred to nitrocellulose membranes and immunoblotted with primary antibodies: rabbit antibody to Flag (Sigma, F7425; 1:5,000 dilution), rabbit antibody to CREB (Cell Signaling Technology, 9197; 1:1,000 dilution), rabbit antibody to phosphorylated CREB (Cell Signaling Technology, 9198; 1:1,000 dilution), rabbit antibody to ATF1 (Millipore, 2302161; 1:1,000 dilution) and mouse antibody to PRKAR1A (BD Biosciences, 610609; 1:500 dilution). Signals were visualized by chemiluminscence after incubation with peroxidase-conjugated secondary antibody.
Staining for phosphorylated CREB. Immunohistochemistry was performed on slides from formalin-fixed, paraffin-embedded samples using a rabbit polyclonal antibody to phosphorylated CREB (Cell Signaling Technology, 9198; 1:600 dilution). To determine the specificity of antibody binding, blocking peptides specific to the antibody were used (Cell Signaling Technology, 1090). All slides were stripped of paraffin in xylene before rinsing in decreasing concentrations of ethanol, and antigen retrieval was performed in boiling 10 mM sodium citrate with 0.05% Tween-20 at pH 6.0. Cells were permeabilized in 0.2% Triton X-100 in PBS and incubated in 3% hydrogen peroxide. Blocking was achieved with 10% BSA in PBS. After incubation with primary and secondary antibodies, slides were stained with diaminobenzidine (DAB) and counterstained with hematoxylin.
An experienced endocrine pathologist determined the percentage of nuclei stained positive for phosphorylated CREB by selecting the most strongly staining area, and at least 100 nuclei were assessed for each tumor. Endothelial cells in the tumor were used as an internal positive control for regions where staining of tumor nuclei was not observed, and the presence of unstained nuclei was used as an internal negative control.
Statistical analysis. The data are summarized as means ± s.e.m. Two-tailed t tests, Mann-Whitney U tests and Fisher's exact tests were used for comparison between two groups. The P value for the probability of an observed recurrent mutation occurring by chance was calculated as a binomial probability using the somatic mutation rate of CNV-negative tumors. Monte Carlo simulations (1 × 10 6 iterations) were performed to calculate the probability of observing mutually exclusive mutations in PRKACA, CTNNB1 and GNAS by chance.
